Department of Dermatology, Alicante University General Hospital, Alicante, Spain.
Department of Pharmacy, Alicante University General Hospital, Alicante, Spain.
Dermatology. 2022;238(1):82-85. doi: 10.1159/000515450. Epub 2021 Apr 22.
Topical 15% resorcinol is commonly used in clinical practice for the treatment of nodules and abscesses in patients with hidradenitis suppurativa (HS). It has been shown to be clinically effective in some small studies, but data on satisfaction perceived by patients are lacking. The Treatment Satisfaction Questionnaire for Medication (TSQM) version 1.4 is a validated measure of patient satisfaction, evaluating four domains: effectiveness, side effects, convenience, and global satisfaction. Our objective was to obtain data from HS patients regarding resorcinol treatment satisfaction and its relationship with clinical and epidemiological variables.
We performed a cross-sectional study providing TSQM version 1.4 questionnaires to HS patients who had been prescribed topical resorcinol during the previous 24 months.
Ninety-two patients answered the questionnaire. Eighty-five out of 92 (92.4%) were Hurley II and 7 Hurley I. The mean total score was 317.5 out of 400 (71.0 points in effectiveness, 93.6 in side effects, 79.3 in convenience, and 73.2 in global satisfaction). Total score was higher in men than in women (329.7 vs. 311.6, p = 0.026) and higher scores on convenience were seen in patients who were not overweight or obese (86.9 vs. 77.1, p = 0.016). Most patients (65, 70.6%) denied having any side effect. 78 (84.8%) of the patients would recommend the treatment.
The results of this study suggest that HS patients treated with resorcinol 15% are very satisfied with this treatment.
15%的间苯二酚在临床上常用于治疗化脓性汗腺炎患者的结节和脓肿。一些小型研究表明其具有临床疗效，但缺乏患者满意度的数据。治疗满意度问卷（TSQM）1.4 版是一种经过验证的患者满意度衡量标准，评估四个方面：疗效、副作用、便利性和整体满意度。我们的目的是从化脓性汗腺炎患者那里获得关于间苯二酚治疗满意度及其与临床和流行病学变量关系的数据。
我们进行了一项横断面研究，向在过去 24 个月内被处方外用间苯二酚的化脓性汗腺炎患者提供 TSQM 1.4 问卷。
92 名患者回答了问卷。92 名患者中有 85 名（92.4%）为 Hurley II 期，7 名 Hurley I 期。总评分平均为 400 分中的 317.5 分（疗效 71.0 分，副作用 93.6 分，便利性 79.3 分，整体满意度 73.2 分）。男性总评分高于女性（329.7 分比 311.6 分，p=0.026），非超重或肥胖患者的便利性评分更高（86.9 分比 77.1 分，p=0.016）。大多数患者（65 名，70.6%）否认有任何副作用。78 名（84.8%）患者会推荐这种治疗方法。
这项研究的结果表明，接受 15%间苯二酚治疗的化脓性汗腺炎患者对这种治疗非常满意。
